11 results about "Eicosatetraenoic acid" patented technology

The invention discloses a heterocyclic aryl or heteroaryl-heteroaryl derivative and application of the heterocyclic aryl or heteroaryl-heteroaryl derivative. The heterocyclic aryl or heteroaryl-heteroaryl derivative of the present invention is a compound of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt of a solvate thereof. The compound disclosed by the invention has good inhibitory activity on a 20-hydroxyeicosatetraenoic acid (20-HETE) signal channel, and has a good medicinal prospect. # imgabs0 #

A use of a nutritional composition in promoting the bidirectional development of the gut and brain via the gut-brain axis. The nutritional composition comprises the following essential components: docosahexaenoic acid, eicosatetraenoic acid, galactooligosaccharide, 1,3-dioleic acid-2-palmitic acid triglyceride, lutein, nucleotide, lactoferrin, casein phosphopeptide, and probiotics. By combining and strengthening multiple functional active components, the gut health and brain cognitive development of the organism can be bidirectionally promoted by means of the microbiota-gut-brain axis. In particular, the present application can promote the regulation of flora in the gut of the organism, increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria related to brain development diseases. The content of butyric acid in the gut can be increased, and the contents of acetic acid and propionic acid are decreased to promote brain and cognitive development.

The invention relates to the technical field of biologic detection of metabolomics, in particular to an OSAHS metabolism marker, a diagnosis model and application of the OSAHS metabolism marker and the diagnosis model. The metabolic marker comprises a red blood cell metabolite and / or a plasma metabolite; erythrocyte metabolites comprise L-aspartic acid, D-ribose-5-diphosphoric acid, cadaverine, 12, 13-epoxy octadecenoic acid, L-arginine, N-acetylmethionine, 5-hydroxyeicosatetraenoic acid, 13-oxo-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 10-tetrahydroxy-9Z, the component A is one or more of 11E-octadecadienoic acid, inosine monophosphate, nicotinamide, alpha-lactose, sphingosine, hydroxy octadecadienoyl or glyceraldehyde-3-phosphoric acid; the plasma metabolite is prepared from one or more of fumaric acid, cadaverine, L-aspartic acid, malic acid, sphingosine-1-phosphoric acid, L-arginine, cysteine-S-sulfate, thiosulfate, gamma-glutamyl alanine, galacturonic acid or vitamin B2.

8Z, 11Z, 14Z, 17Z-eicosatetraenoic acid (ETA) and / or 10Z, 13Z, 16Z-docosa-10,l 3, 16-trienoic acid (DTA) have been shown to have anti-neuroinflammatory properties and suitable for use in the treatment of neurodegenerative disease, such as Alzheimer's disease. The anti-neuroinflammatory effect of using ETA and / or DTA can be surprisingly, and optionally synergistically increased by using ETA and / or DTA in combination with eicosapentaenoic acid (EPA),docosahexaenoic acid (DHA), stearidonic acid (6, 9, 12, 15 -octadecatrienioc acid) (SDA), gamma linolenic acid (6, 9, 12-octadecatrienioc acid) (GLA), dihomo γ linolenic acid (8, 11, 14-eicosatraenoic acid) (DGLA), and / or 7, 10, 13, 16, 19-docosapentaenoic acid (DPA), preferably docosahexaenoic acid (DHA).

The application relates to a microbial preparation passing through the rumen, a preparation method and application thereof. The microbial preparation passing through the rumen comprises microbial powder and a coating material coated on the surface of the microbial powder. The coating material comprises protective fat. The total weight of fatty acids in the microbial preparation passing through the rumen is 100%, the fatty acids comprise 70wt%-80wt% of palmitic acid and stearic acid, <=9wt% of oleic acid, 5wt%-15wt% of polyunsaturated fatty acids and a residual amount of non-target fatty acids, the mass ratio of the palmitic acid to the stearic acid is 1:1-2:1, the polyunsaturated fatty acids are selected from at least one of docosahexaenoic acid, eicosatetraenoic acid and eicosapentaenoic acid, and the mass ratio of the microbial powder to the protective fat is 2:3-3:2. The microbial preparation passing through the rumen described in the application is used as a feed additive for feeding ruminants such as cows, and can realize the dual improvement of the production performance of the cows and the nutrition strengthening of the milk.

The present invention provides a method for determining whether a subject is suffering from post-traumatic stress disorder (PTSD) or acute stress disorder (ASD), the method comprising measuring, in a sample derived from the subject, the amount of at least one selected from the group consisting of 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE), 15-hydroxy-5,8,11,13-eicosatetraenoic acid (15-HETE), and 13-hydroxy-9(Z),11(E)-octadecadienoic acid (13-(Z,E)-HODE).

The invention relates to the technical field of food, in particular to a intelligence unit composition capable of simultaneously improving short-term memory and long-term memory and improving immunity and application of the intelligence unit composition. The intelligence unit composition is prepared from the following components in parts by weight: 120 to 310 parts of unsaturated fatty acid A, 20 to 200 parts of eicosatetraenoic acid, 25 to 160 parts of oleic acid, 35 to 65 parts of phosphatidylserine and 50 to 100 parts of walnut oil, the unsaturated fatty acid A comprises at least one of DHA (docosahexaenoic acid) and alpha-linolenic acid. The intelligence unit composition has the advantages that short-term memory and long-term memory can be remarkably improved at the same time, and the effect of improving immunity is good.

The invention discloses application of a marker metabolite in identification of different harvest periods of porphyra haitanensis, and belongs to the field of food analysis and detection. The marker metabolites comprise lysophosphatidylethanolamine 15: 1 *, 2 '-deoxyguanosine, L-gamma-glutamine-L-leucine, lysophosphatidylethanolamine 22: 5, lysophosphatidylethanolamine 17: 1 *, 3, 4-dihydroxyphenylacetic acid *, 12S-hydroxy-5Z, 8Z, 10E, 14Z-eicosatetraenoic acid, lysophosphatidylcholine 18: 0 (2n isomerization) and 1-(2, 4-dihydroxyphenyl)-1-(2, 4-dihydroxyphenyl)-1-(2, 4-dihydroxyphenyl)-1-(2, 4-dihydroxyphenyl)-1-(2, 4-dihydroxyphenyl)-1-(2, 4-dihydroxyphenyl)-1-(2, 4- )-3-(((2-(dimethylamino) ethyoxyl) (hydroxy) phosphoryl) oxy) propan-2-yl palmitate *, and the like. The screening method of the marker metabolite reveals the difference of the porphyra haitanensis in different harvesting periods, the technology is advanced, the experimental result is reliable, and an excellent method is provided for quality identification and quality evaluation of the porphyra haitanensis.

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

The invention relates to the technical field of compositions, and particularly discloses an application of a special medical-purpose formula food composition suitable for infants allergic to food protein to the non-treatment purpose of improving eosinophilic esophagitis. The special medical use formula food composition suitable for infants allergic to food proteins comprises docosahexaenoic acid, eicosatetraenoic acid and nucleotides. The special medical formula food composition suitable for infants allergic to food protein provided by the invention can improve esophageal epithelial hyperplasia and reduce the level of IL-13 cell factors by increasing the number of bifidobacteria and reducing the number of enterobacter and eosinophilic granulocytes in esophageal tissue, so that the eosinophilic granulocytic esophagitis is remarkably improved.

The application relates to the technical field of judging or confirming hypophthalmichthys nobilis, and particularly relates to a fatty acid biomarker for distinguishing wild and cultured hypophthalmichthys nobilis, a method and an application. The biomarker comprises at least one of tetradecanoic acid, cis, cis, cis-9, 12, 15-octadecatrienoic acid, cis-5, 8, 11, 14-eicosatetraenoic acid and cis-5, 8, 11, 14, 17-eicosapentaenoic acid. The biomarker can accurately distinguish wild and cultured hypophthalmichthys nobilis, provide scientific basis and technical support for relevant law enforcement departments, strengthen supervision and strike force of illegal fishing behavior in the Yangtze River basin, reduce overfishing of wild resources, and further provide a technical basis for better management and protection of hypophthalmichthys nobilis resources.